Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aligos Therapeutics Inc
(NQ:
ALGS
)
0.7000
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 30, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
0.7000
Bid (Size)
0.5500 (1)
Ask (Size)
0.8000 (1)
Prev. Close
0.7000
Today's Range
0.7000 - 0.7000
52wk Range
0.5388 - 2.410
Shares Outstanding
42,940,089
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
November 20, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Why Is Tharimmune (THAR) Stock Down 8% Today?
November 20, 2023
Tharimmune stock is falling after the company announced a reverse stock split for THAR shares that goes into effect later today.
Via
InvestorPlace
Performance
YTD
-25.53%
-25.53%
1 Month
+16.67%
+16.67%
3 Month
-18.70%
-18.70%
6 Month
-36.36%
-36.36%
1 Year
-30.00%
-30.00%
More News
Read More
Why Is Aligos Therapeutics (ALGS) Stock Down 5% Today?
November 20, 2023
Via
InvestorPlace
Why Applied UV Shares Are Trading Higher By Around 96%; Here Are 20 Stocks Moving Premarket
November 20, 2023
Via
Benzinga
Earnings Outlook For Aligos Therapeutics
November 01, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 20, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
November 20, 2023
Via
InvestorPlace
Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile
November 13, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
November 10, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecule,
November 07, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data
November 03, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
November 02, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
October 27, 2023
Via
Benzinga
Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023
October 26, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics To Present Late Breaking Poster on ALG-000184, its CAM-E Drug Candidate, at The Liver Meeting® 2023
October 25, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Why Aligos Therapeutics (ALGS) Stock Is Nosediving
October 23, 2023
Via
Benzinga
Aligos Therapeutics Announces $92 Million Private Placement Financing
October 23, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558
October 03, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
September 21, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
August 03, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Announce Second Quarter Results on August 03, 2023
July 27, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009
July 19, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
June 21, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
June 07, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference
May 24, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.